- Stocks
- Healthcare
- NASDAQ: DNLI

Price (delayed)

$50.48

Market cap

$6.12B

P/E Ratio

81.42

Dividend/share

N/A

EPS

$0.62

Enterprise value

$5.75B

The quick ratio has soared by 110% year-on-year and by 26% since the previous quarter

Denali Therapeutics's debt has decreased by 6% YoY

The EPS has soared by 128% YoY but it has decreased by 4.6% from the previous quarter

The net income has soared by 127% year-on-year but it is down by 19% since the previous quarter

What are the main financial stats of DNLI

Market
Valuations
Earnings

Shares outstanding

121.19M

Market cap

$6.12B

Enterprise value

$5.75B

Price to earnings (P/E)

81.42

Price to book (P/B)

5.53

Price to sales (P/S)

17.95

EV/EBIT

97.77

EV/EBITDA

85.79

EV/Sales

16.91

Revenue

$339.98M

EBIT

$58.82M

EBITDA

$67.03M

Free cash flow

$415.39M

Per share
Balance sheet
Liquidity

EPS

$0.62

Free cash flow per share

$3.44

Book value per share

$9.14

Revenue per share

$2.81

TBVPS

$12.8

Total assets

$1.55B

Total liabilities

$442.51M

Debt

$67.79M

Equity

$1.11B

Working capital

$1.38B

Debt to equity

0.06

Current ratio

26.22

Quick ratio

25.88

Net debt/EBITDA

-5.48

Margins
Efficiency
Dividend

EBITDA margin

19.7%

Gross margin

100%

Net margin

17%

Operating margin

15.1%

Return on assets

4.8%

Return on equity

6.4%

Return on invested capital

6.9%

Return on capital employed

3.9%

Return on sales

17.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Denali Therapeutics stock price performed over time

Intraday

-1.08%

1 week

-6.76%

1 month

-34.44%

1 year

115.54%

YTD

-39.73%

QTD

-35.65%

How have Denali Therapeutics's revenue and profit performed over time

Revenue

$339.98M

Gross profit

$339.98M

Operating income

$51.47M

Net income

$57.86M

Gross margin

100%

Net margin

17%

The net income has soared by 127% year-on-year but it is down by 19% since the previous quarter

DNLI's operating income has surged by 122% year-on-year but it is down by 18% since the previous quarter

Denali Therapeutics's net margin has soared by 102% YoY but it has decreased by 20% from the previous quarter

DNLI's operating margin has surged by 102% year-on-year but it is down by 19% since the previous quarter

What is Denali Therapeutics's growth rate over time

What is Denali Therapeutics stock price valuation

P/E

81.42

P/B

5.53

P/S

17.95

EV/EBIT

97.77

EV/EBITDA

85.79

EV/Sales

16.91

The EPS has soared by 128% YoY but it has decreased by 4.6% from the previous quarter

Denali Therapeutics's equity has surged by 103% YoY but it has decreased by 3.9% QoQ

DNLI's price to book (P/B) is 9% less than its last 4 quarters average of 6.1

The stock's price to sales (P/S) is 76% less than its last 4 quarters average of 75.9

How efficient is Denali Therapeutics business performance

The return on invested capital has surged by 117% year-on-year but it has declined by 32% since the previous quarter

The return on assets has surged by 114% year-on-year but it has declined by 32% since the previous quarter

The return on equity has surged by 114% year-on-year but it has declined by 30% since the previous quarter

The ROS has soared by 102% YoY but it has decreased by 19% from the previous quarter

What is DNLI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for DNLI.

How did Denali Therapeutics financials performed over time

DNLI's total liabilities has surged by 194% year-on-year but it is down by 2.5% since the previous quarter

The company's total assets has surged by 122% YoY but it fell by 3.5% QoQ

Denali Therapeutics's debt is 94% less than its equity

Denali Therapeutics's equity has surged by 103% YoY but it has decreased by 3.9% QoQ

DNLI's debt to equity has dropped by 54% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.